Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment

BACKGROUND: Cabotegravir (CAB) is an integrase inhibitor in phase 3 clinical trials for the treatment and prevention of HIV. CAB undergoes hepatic metabolism primarily via UGT1A1; thus hepatic impairment has the potential to affect CAB exposure. METHODS: This was a multi-center, single-dose, open-la...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Open Forum Infect Dis
Hoofdauteurs: Shaik, Jafar Sadik, Ford, Susan, Lou, Yu, Zhang, Zhiping, Bakshi, Kalpana, Tenorio, Allan, Trezza, Christine, Spreen, William, Patel, Parul
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2017
Onderwerpen:
Abstracts
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5631467/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1084
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items